Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

 

NEWSROOM

  • Oct 10

    Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019
  • Sep 20

    The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

EVENTS

Events
  • REGENERON PHARMACEUTICALS Q3 2019 EARNINGS CONFERENCE CALL
    Nov 5
    8:30 AM EST
    Nov 5, 2019 | 8:30 AM EST